MPO’s Most-Read Stories This Week—Sept. 14

Amidst a news cycle of personnel changes, FDA clearances, and exclusive peeks at tooling transfers and mental health technologies, a simple name brand adjustment was the top choice among MPO website visitors this past week.

Johnson & Johnson’s decision to simplify its name brand garned the most pageviews, significantly outpacing digital click rates generated by both Withings and ENDRA Life Sciences.

J&J has decided to no longer use individual monikers for its various medical technology businesses—i.e., Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and CERENOVUS. All those businesses now fall under the Johnson & Johnson MedTech brand name. Considered the next step of Johnson & Johnson’s updated brand and visual identity announced last fall, the change is not expected to impact medical technology products and solutions currently offered to customers.

Although it was runner-up to J&J’s name brand announcement, Withings nevertheless generated significant traffic with word of the FDA clearance of its Sleep Rx Mat, an advanced sleep device clinically validated for at-home use in helping diagnose obstructive sleep apnea as well as providing sleep analysis and heart rate estimation. The unobtrusive mat requires a one-time set up, fits under any mattress, eliminating the need for masks or cumbersome equipment. Once set up, it provides detailed analysis of sleep, breathing, and cardiovascular activity throughout the night. The mat is available in the United States by prescription as part of clinical sleep management or remote patient monitoring program.

ENDRA Life Sciences attracted website visitors too, though a Q&A on tooling transfers proved more popular with MPO loyalists. Still, the company managed to gain readers’ attention with an executive team overhaul. With former CEO Francois Michelon having stepped down from his post to pursue other endeavors, the firm’s Board of Directors has appointed Alexander Tokman as his temporary replacement (acting CEO). The company also has welcomed to its senior management team Ziad Rouag as head of Regulatory and Clinical Affairs and Richard Jacroux as chief financial officer (CFO).

1. J&J Updates MedTech Company Brand Identity

2. FDA Clears First Contactless Sleep Apnea Diagnostic Device

3. Transferring Tooling When Making Supplier Changes—A Medtech Makers Q&A

4. CEO Vacancy Triggers Management Shuffle at ENDRA Life Sciences

5. Technological Innovations That Can Improve Mental Health